Company: LNAI
Filing Date: 2025-10-15
Form Type: DEF 14A
Source: 0001731122-25-001378
Chunk: 12

Company: Lunai Bioworks Inc.
Filing Date: 2025-10-15
Form: DEF 14A
Chunk 12
---
 or until their successors are elected and qualified
or until their earlier death, resignation or removal. Our Board believes that all of the Company Nominees possess personal and professional
integrity, good judgment, a high level of ability and business acumen.

If a quorum is present, the Company
Nominees will be elected by a plurality of the voting power of the shares present in person or represented by proxy at the Annual Meeting
and entitled to vote on the election of directors. Abstentions and broker non-votes have no effect on the vote. The four Company Nominees
receiving the highest number of affirmative votes will be elected directors of the Company. Shares of voting stock represented by executed
proxies will be voted, if authority to do so is not withheld, FOR the election of the four nominees named above. Proxies cannot be voted
for a greater number of individuals than the number of nominees named. Should any Company Nominee become unable or unwilling to accept
nomination or election, the proxy holders may vote the proxies for the election, in his or her stead, of any other person the Board may
nominate or designate. Each Company Nominee has agreed to serve, if elected, and the Board has no reason to believe that any Company Nominee
will be unable to serve as a director.

The biographies of the Company
Nominees are as follows:

David Weinstein

On October 14, 2024, the board
of directors of the Company appointed David Weinstein, age 65, Chief Executive Officer of the Company and a member of the Board. Immediately
prior to joining the Company, Mr. Weinstein was a Managing Partner, Investment Banking at Dawson James Securities, Inc. where he has worked
since 2005. While at Dawson James, Mr. Weinstein directly sourced over $300 million in investments for small-cap biotech and healthcare
companies. He also spearheaded the merger of two healthcare companies in personalized cancer diagnostics and assisted in its uplisting
on Nasdaq. Mr. Weinstein received his Bachelor of Arts in Liberal Arts from St. John’s College and a Masters in Public Management
from the University of Maryland.

<div align='center'>8</div>

Douglas W. Calder

Since 2015, Mr. Calder has served as president and
a director of Vycellix, Inc and its subsidiaries and affiliates. He has also served as a member of the board of directors for Zevra Therapeutics,
Inc. (NASDAQ: ZV